Roger Stupp
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.02%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
Papers in
- Genetics 200
- Glioma Diagnosis and Treatment 195
-
- Brain Metastases and Treatment 62
- Lung Cancer Treatments and Mutations 24
- Co-authors
- Michael Weller (78 shared papers)Martin J. van den Bent (72 shared papers)Thierry Gorlia (55 shared papers)R.O. Mirimanoff (21 shared papers)Monika E. Hegi (69 shared papers)Warren Mason (20 shared papers)J. Gregory Cairncross (6 shared papers)Robert C. Janzer (7 shared papers)
- Journals
- Journal of Clinical Oncology (59 papers)Neuro-Oncology (41 papers)Annals of Oncology (25 papers)European Journal of Cancer (19 papers)Clinical Cancer Research (13 papers)
- Partner nations
- SwitzerlandUnited StatesGermany
In The Last Decade
Roger Stupp
366 papers receiving 49.6k citations
Roger Stupp's Hit Papers
Peers
Comparison fields: 5 of 169
- Genetics 27.4k
- Cancer Research 8.2k
- Pulmonary and Respiratory Medicine 9.0k
- Oncology 7.3k
- Radiology, Nuclear Medicine and Imaging 4.9k
Countries citing papers authored by Roger Stupp
This map shows the geographic impact of Roger Stupp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Stupp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Stupp more than expected).
Fields of papers citing papers by Roger Stupp
This network shows the impact of papers produced by Roger Stupp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Stupp. The network helps show where Roger Stupp may publish in the future.
Co-authors
The 25 scholars most cited alongside Roger Stupp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 378 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Hit paper breakdown → | 2005 | 16232 |
| 2 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 5292 |
| 3 | Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group Hit paper breakdown → | 2010 | 2758 |
| 4 | Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial Hit paper breakdown → | 2012 | 874 |
| 5 | Glioma Hit paper breakdown → | 2015 | 814 |
| 6 | Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial Hit paper breakdown → | 2013 | 749 |
| 7 | Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity Hit paper breakdown → | 2008 | 662 |
| 8 | Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide Hit paper breakdown → | 2004 | 634 |
| 9 | Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide Hit paper breakdown → | 2002 | 632 |
| 10 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Hit paper breakdown → | 2009 | 579 |
| 11 | High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 578 |
| 12 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma Hit paper breakdown → | 2014 | 573 |
| 13 | cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” Hit paper breakdown → | 2018 | 568 |
| 14 | Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma Hit paper breakdown → | 2008 | 567 |
| 15 | 2004 | 416 | |
| 16 | 2007 | 414 | |
| 17 | 2007 | 399 | |
| 18 | 2006 | 387 | |
| 19 | 2011 | 365 | |
| 20 | 2010 | 363 |
About Roger Stupp
Roger Stupp is a scholar working on Genetics, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology and Cancer Research, having authored 378 papers that have together received 50.4k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (195 papers), Brain Metastases and Treatment (62 papers), Radiomics and Machine Learning in Medical Imaging (27 papers), Cancer Genomics and Diagnostics (26 papers), Lung Cancer Treatments and Mutations (24 papers), Cancer Treatment and Pharmacology (22 papers), Cancer, Hypoxia, and Metabolism (19 papers) and Epigenetics and DNA Methylation (17 papers). The work is most often cited by research in Genetics (27.4k citations), Cancer Research (8.2k citations), Pulmonary and Respiratory Medicine (9.0k citations), Oncology (7.3k citations) and Radiology, Nuclear Medicine and Imaging (4.9k citations). Roger Stupp has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include Michael Weller, Martin J. van den Bent, Thierry Gorlia, R.O. Mirimanoff, Monika E. Hegi, Warren Mason, J. Gregory Cairncross, Robert C. Janzer, Alba A. Brandes and Denis Lacombe. Their work appears in journals such as Journal of Clinical Oncology, Neuro-Oncology, Annals of Oncology, European Journal of Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.